French regulators report GMP failings at Anuh Pharma API processing plant

By Gareth Macdonald

- Last updated on GMT

Source: Anuh Pharma
Source: Anuh Pharma

Related tags Pharmaceutical drug Pharmacology Manufacturing

Anuh Pharma has breached GMP rules at its API processing facility in Boisar, India say French regulators who visited the site last month.

According to a report​ published today, ANSM inspectors observed 24 deficiencies from good manufacturing practices (GMP) at the plant, which provides particle processing – micronization - services.

The major deviation was Anuh’s failure to pass details of its suppliers on to customers to which it sold processed active pharmaceutical ingredients (API).

The ANSM team also reported that azithromycin supplied to Europe labelled as being manufactured by Anuh was actually made by a non-compliant Chinese supplier called Hebei Dongfeng Pharmaceutical.

The inspectors also criticised Anuh’s document management practices after discovering several API repacking records and purchasing orders within a "pile of rubble on the other side of a wall​."

They wrote that: “The findings reveal a critical non-compliance of the quality system of the company as a whole. Moreover, due to the severe lack of transparency of the company regarding its manufacturing activities, there is no assurance as regards to the origin of every batch of active substances claimed to have been manufactured by the company at the Boisar site.

Consequently, it is considered that the identified risks are applicable to all active substances manufactured at the site​.”

GMP certificate

The inspectors also suggested that “withdrawal of current valid EU GMP certificate issued by the Agencia Italiana del Farmaco (IT/E/GMP/9/2013)​” be considered.

They also said: “The site has been issued a statement of non-compliance and active substances manufactured by the site should not be used for the manufacturing of medicinal products.”

The EDQM has yet to decide whether to withdraw CEPs issued to Anuh.

Related news

Show more

Related products

show more

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 09-Jun-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Related suppliers

Follow us


View more